FIELD: medicine; pharmaceutics.
SUBSTANCE: invention relates to pharmaceutical compositions for treating diseases or conditions associated with plasma kallikrein activity. Disclosed is a pharmaceutical composition for treating a disease or condition associated with plasma kallikrein activity, containing: (i) a pharmaceutically acceptable carrier, diluent or excipient and (ii) a compound of formula (I), wherein R5, R6, R7, A, B, W, X, Y and Z are as defined in the claims, or a pharmaceutically acceptable compound thereof salt or solvate. Also disclosed are a compound of formula (I), its use in a method of treating a disease or condition which is associated with plasma kallikrein activity, a corresponding method of treating, as well as a pharmaceutical composition having the ability to inhibit plasma kallikrein activity.
EFFECT: content of low-molecular compounds in the pharmaceutical composition, which selectively inhibit plasma kallikrein, improves oral accessibility.
24 cl, 15 tbl, 140 ex
Title | Year | Author | Number |
---|---|---|---|
N-((HET)ARYLMETHYL)-HETEROARYL-CARBOXAMIDE COMPOUNDS AS PLASMA KALLIKREIN INHIBITORS | 2015 |
|
RU2707870C2 |
PYRAZOLE DERIVATIVES AS KALLIKREIN INHIBITORS | 2017 |
|
RU2739447C2 |
BICYCLIC DIHYDROPYRIMIDINECARBOXAMIDE DERIVATIVES AS RHO-KINASE INHIBITORS | 2017 |
|
RU2778478C2 |
PYRAZOLO[1,5-A]PYRIMIDINYLCARBOXAMIDES AND THEIR USE FOR THE TREATMENT OF PATHOLOGICAL CONDITIONS | 2017 |
|
RU2799332C2 |
POLYMORPHIC MODIFICATIONS OF N-[(3-FLUORO-4-METHOXYPYRIDINE-2-YL)METHYL]-3-(METHOXYMETHYL)-1-({ 4-[(2-OXOPYRIDINE-1-YL)METHYL]PHENYL} METHYL)PYRAZOLE-4-CARBOXAMIDE AND THEIR SALTS | 2017 |
|
RU2756273C2 |
ANILIDES OF AMINO ACIDS AS LOW-MOLECULAR MODULATORS IL-17 | 2019 |
|
RU2815505C2 |
PYRAZOLOPYRIMIDINE-BASED JAK INHIBITING COMPOUNDS AND METHODS | 2010 |
|
RU2567238C2 |
PHARMACEUTICALLY ACTIVE COMPOUNDS AS Axl INHIBITORS | 2011 |
|
RU2573834C2 |
INHIBITING JAK COMPOUNDS BASED ON PYRAZOLOPYRIMIDINE AND METHODS | 2010 |
|
RU2675857C2 |
ENZYME INHIBITORS | 2014 |
|
RU2674028C2 |
Authors
Dates
2024-06-25—Published
2015-11-26—Filed